PYY3-36 / Novo Nordisk - LARVOL DELTA

pH Controlled transient cyclization of peptides for increased stability towards oral delivery. (PubMed, Chemistry) - "We studied the stability against simulated gastric fluid (SGF) at different pH and the ability of cyclic peptides to linearize. This led to PYY3-36 analogues with pH responsive linearization for increased stability."

Journal • Diabetes • Metabolic Disorders • Oncology

Neo-Glycolipid Oximes as Intestinal Permeation Enhancers for Peptide Hormone PYY3-36. (PubMed, Chemistry) - "Finally, neo-glycolipids were evaluated as permeation enhancers for the peptide hormone PYY3-36. Glucose- and maltose-derived neo-glycolipids based on decanoic and dodecanoic acid showed promising enhancements in PYY3-36 permeation while maintaining good cellular compatibility, relevant for oral delivery of obesity treatments."

Journal • Genetic Disorders • Obesity

APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE (clinicaltrials.gov) - P=N/A; N=40; Not yet recruiting; Sponsor: University College, London

Clinical • New trial • Genetic Disorders • Obesity

Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries. (PubMed) - "Combination carboplatin-pemetrexed is an effective and well-tolerated treatment, associated with a median PFS of 5.1?months and a clinical benefit in at least 57% of the patients treated."

Journal • Biosimilar • Esophageal Cancer • Head and Neck Cancer • Oncology

[VIRTUAL] The Vagus Nerve and the Hypothalamus Mediate Different Aspects of the Anorectic Effects of PYY3-36 (ENDO-I 2020) - "NG-Y2R-KD animals had 60% reduction in NG Y2R mRNA but remained responsive to cholecystokinin, a positive control of vagal functionality. This is the first example of receptor specific adult vagal deafferentation in mice. The Nav1.8-Y2R-KD model achieved 30% receptor KD."

Genetic Disorders • Obesity

Modified peptide YY molecule attenuates the activity of NPY/AgRP neurons and reduces food intake in male mice. (PubMed, Endocrinology) - "NNC0165-1273 is non-nauseating and stimulates a satiety response through, at least in part, a direct action on hypothalamic NPY/AgRP neurons. Modification of PYY3-36 to produce compounds with increased affinity to Y2 receptors may be useful as anti-obesity therapies in humans."

Journal • Preclinical

A Clear Difference Emerges in Hormone Patterns Following a Standard Midday Meal in Young Women Who Regularly Eat or Skip Breakfast. (PubMed, J Nutr) - P=N/A; "The objective of this study was to compare hormonal responses, including insulin, leptin, glucagon-like peptide-1, ghrelin, peptide YY (PYY3-36), and cholecystokinin (CCK), between habitual breakfast eaters (Br-Es) and habitual skippers (Br-Ss) to a standard midday meal...The different patterns may be short-lived or may impact metabolism later in the day. This report is a secondary analysis of a trial registered at clinicaltrials.gov as NCT01427556."

Clinical • Journal